Clinical Evaluation
A prospective clinical study investigating the efficacy and safety of RenoVō® for wound healing using an equine distal limb-wound healing model is currently ongoing in partnership with the Oklahoma State University College of Veterinary Medicine. In addition, a prospective case study investigating the outcomes of approximately 200 horses with soft tissue and orthopedic injuries using RenoVō® is nearing conclusion.
Cases Under Evaluation Include:
- Stifles for meniscal lesions
- Carpus for intercarpal ligament tear
- Lower hock joints
- Coffin joints
- Desmitis of flexor tendons
- Proximal suspensory ligament desmitis
- Suspensory branches
- Collateral ligaments of the coffin joint
- Deep digital flexor tendon tear
- Superficial digital flexor tendon tear
Potential Advantages of RenoVō®
The ready availability of a convenient allograft potentiates clinical use without the time lapse for culturing cells or harvesting techniques required for autologous therapies. Further, cytokine and growth factor profiles can vary dramatically between patients for a selected autologous product. The protein content and reproducibility of each donor tissue may offer a more consistent product with similar or superior regenerative capacity. RenoVō® is cryopreserved and maintained frozen before use, so as to preserve beneficial proteins that may not survive lyophilization. Clinicians currently using autologous stem cell or IRAP II™ System therapy should consider the use of RenoVō® to achieve similar or improved clinical outcome
The Front Range Equine Performance Team is proud to be the first veterinarians in Colorado and Wyoming to use this new regenerative therapy. We work closely with the company and the veterinarians who pioneered this exciting new treatment in veterinary medicine to determine which patients RenoVō® will benefit.
In the following video, Dr. Marshall-Gibson talks about her experience with RenoVō® and why she may choose to treat with RenoVō® over another treatment option.
